BioSpace News Archive

- Replimune Group Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic® platform, today announced it will host an investor event to present updated data from its Phase 2 skin cancer cohorts combining RP1 with Opdivo® and data from its Phase 1 study of RP2 alone and in combination with Opdivo.

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced its Annual General Meeting (“AGM”) will be held on May 5, 2021 at 10:00 a.m. ET

Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, announced today that it will present two digital presentations at the American Society of Gene and Cell Therapy (ASGCT) 24 th Annual Meeting, to be held virtually May 11-14, 2021.

EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, announced a new analysis from the MAGNIFY-MS sub-study showing a specific immune repopulation pattern in patients with relapsing multiple sclerosis (RMS) treated with MAVENCLAD® (cladribine) tablets,

I-Mab (the “Company”) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the Company has filed its annual report on Form 20-F for the full year ended December 31, 2020 with the U.S. Securities and Exchange Commission

Cosmo Pharmaceuticals N.V. invites investors, financial analysts as well as business and trade media to a conference call Q&A session on the 4th of May 2021 to discuss GI Genius™, the first device approved by the US Food and Drug Administration[1] that uses artificial intelligence to help detect potential signs of colon cancer.

CARISMA Therapeutics Inc. , a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced findings from two studies accepted for virtual presentation at The American Society of Gene & Cell Therapy (ASGCT) 24th Annual Meeting on Tuesday, May 11 – Friday, May 14 .

Led by Nextech Invest and RA Capital Management, with participation from new investors Fidelity Management & Research Company LLC, Redmile Group, Wellington Management, Surveyor Capital, PFM Health Sciences, and Logos Capital and existing investors Funding will support development of ecDNA directed therapeutic programs and ecDNA companion diagnostic to address oncogene amplified cancers

Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today announced positive results for the first ten COVID-19 patients treated with Zofin™ in India.

Paragonix Technologies announced the presentation of the First Report of the GUARDIAN Registry1 at the International Society for Heart and Lung Transplantation 2021 Annual Meeting